2022 World Conference on Lung Cancer (ePosters)-EP08.02-159. Post Hoc Analyses of Dacomitinib-Associated Skin Disorders and Efficacy in the ARCHER 1050 Study

Pdf Summary

A recent study investigated the association between skin-related adverse events (AEs) and the efficacy of dacomitinib in patients with advanced non-small cell lung cancer (NSCLC) who have an epidermal growth factor receptor (EGFR) mutation. The study analyzed data from the ARCHER 1050 trial, which compared the safety and efficacy of dacomitinib versus gefitinib in previously untreated patients with EGFR-mutant NSCLC. The findings showed that patients who experienced grade 2 skin-related AEs had improved objective response rate, progression-free survival, and overall survival compared to those who did not experience these AEs. The study also found that skin disorders can generally be managed through dose reduction rather than treatment discontinuation. These findings are consistent with previous reports of the association between skin-related AEs and improved efficacy of EGFR tyrosine kinase inhibitors. The study suggests that grade 2 dacomitinib-associated skin disorders may serve as a potential clinical biomarker for predicting efficacy outcomes in patients with advanced EGFR-mutant NSCLC. Further large-scale validation studies are warranted to confirm these findings. Dacomitinib is a second-generation EGFR tyrosine kinase inhibitor that has been approved for the first-line treatment of patients with metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution in various countries. Skin-related AEs are common in patients treated with EGFR inhibitors, and potent inhibitors like dacomitinib are associated with a higher prevalence of these AEs. However, the study indicates that these AEs may be associated with better treatment outcomes. Overall, these findings suggest that monitoring and managing dacomitinib-associated skin disorders may be an important aspect of treatment for patients with advanced EGFR-mutant NSCLC.

Asset Subtitle

Lin Wu

Meta Tag

Speaker Lin Wu

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

skin-related adverse events

efficacy

dacomitinib

advanced non-small cell lung cancer

epidermal growth factor receptor mutation

ARCHER 1050 trial

skin disorders

EGFR tyrosine kinase inhibitors

clinical biomarker

metastatic NSCLC